Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03971409
Title Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe)
Acronym InCITe
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hope Rugo, MD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.